Nizar M. Tannir, MD, FACP

Nizar M. Tannir, MD, FACP, discusses unmet needs for patients with rare kidney tumors and how these needs may be addressed in the future.

Nizar Tannir, MD, FACP, presents extended follow-up data assessing the combination of nivolumab and ipilimumab compared with sunitinib in the frontline setting of patients with advanced renal cell carcinoma (RCC).

Nazir Tannir, MD, FACP, discusses the efficacy of the combination of telaglenastat and cabozantinib in patients with metastatic renal cell carcinoma, as demonstrated in the phase 2 CANTATA trial.

Nizar M. Tannir, MD, FACP, from The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.